BlackRock Health Sciences Term Trust (NYSE:BMEZ) Shares Down 1.2% – What’s Next?

BlackRock Health Sciences Term Trust (NYSE:BMEZ)’s stock price was down 1.2% during mid-day trading on Thursday . The stock traded as low as $16.50 and last traded at $16.5420. 103,693 shares traded hands during mid-day trading, a decline of 51% from the average session volume of 210,301 shares. The stock had previously closed at $16.75.

BlackRock Health Sciences Term Trust Stock Performance

The stock’s fifty day moving average is $16.05 and its 200-day moving average is $14.99.

Institutional Investors Weigh In On BlackRock Health Sciences Term Trust

Several large investors have recently modified their holdings of BMEZ. Saba Capital Management L.P. bought a new stake in BlackRock Health Sciences Term Trust in the 1st quarter valued at $10,907,000. Calamos Advisors LLC bought a new position in BlackRock Health Sciences Term Trust during the 1st quarter worth about $740,000. Lazard Asset Management LLC increased its holdings in BlackRock Health Sciences Term Trust by 64.2% during the 1st quarter. Lazard Asset Management LLC now owns 621,604 shares of the company’s stock worth $8,926,000 after purchasing an additional 243,054 shares in the last quarter. Rivernorth Capital Management LLC raised its stake in shares of BlackRock Health Sciences Term Trust by 24.8% in the 1st quarter. Rivernorth Capital Management LLC now owns 809,196 shares of the company’s stock valued at $11,620,000 after purchasing an additional 160,629 shares during the period. Finally, Kestra Advisory Services LLC raised its stake in shares of BlackRock Health Sciences Term Trust by 3,561.5% in the 1st quarter. Kestra Advisory Services LLC now owns 62,246 shares of the company’s stock valued at $894,000 after purchasing an additional 60,546 shares during the period.

BlackRock Health Sciences Term Trust Company Profile

BlackRock Health Sciences Term Trust (NYSE: BMEZ) is a closed-end management investment company organized as a Delaware statutory trust. Launched in March 2020, BMEZ seeks to provide total return through a combination of current income and capital appreciation by investing primarily in equity and equity-related securities of companies in the health sciences sector. The trust is structured with a fixed termination date in October 2030, at which time shareholders will vote on its liquidation, extension or conversion.

The fund’s investment portfolio is diversified across subsectors within health sciences, including biotechnology, pharmaceuticals, medical devices, diagnostics and healthcare services.